DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session
Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced encouraging new clinical data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of iodine evuzamitide (124I-AT-01), the company’s pan-amyloid binding peptide in development as a radiotracer for the diagnosis of systemic amyloidosis. These data were included in poster presentations at the American College of Cardiology (ACC) Annual Scientific Session and Expo taking place April 2-4, 2022, in Washington, D.C.
The Phase 1/2 trial evaluated the ability of AT-01 to detect amyloid deposits by PET/CT imaging in patients with diverse forms of systemic amyloidosis. The trial enrolled 25 patients with AL amyloidosis, 20 with ATTR amyloidosis, 5 healthy subjects, 2 asymptomatic TTRv subjects and 5 patients with either ALECT2, AGel, ALys or AapoA1 amyloidosis.
Source: www.globenewswire.com
Share
myBinder
Related Content
-
people & placesMichelle O’Shaughnessy, MDMichelle O’Shaughnessy, MB BCh, MS, ...
-
people & placesRobert A. Kyle, MDRobert A. Kyle is a Hematology specialis...
-
videos & visualsDylan’s Amyloidosis Storyhttps://www.youtube.com/watch?v=G3Ec14rA...
-
educationAmyloidosis and its Management: Amyloid NeuropathiesThe amyloid neuropathies are rare, rapid...
-
educationRenal amyloidosisAmyloidosis is a rare disease caused by ...
-
educationWild Type Transthyretin Amyloidosis (ATTRwt): An OverviewWild-type ATTR is also referred to as AT...
-
educationCardiac Amyloidosis: An Updated Review With Emphasis on Diagnosis and Future DirectionsCardiac amyloidosis occurs because of ab...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.